|1.||Wang-Weigand, Sherry: 17 articles (10/2011 - 06/2006)|
|2.||Roth, Thomas: 11 articles (10/2011 - 03/2005)|
|3.||Cardinali, Daniel P: 10 articles (05/2012 - 01/2007)|
|4.||Zhang, Jeffrey: 7 articles (04/2009 - 01/2006)|
|5.||Brown, Gregory M: 6 articles (05/2012 - 06/2009)|
|6.||Pandi-Perumal, Seithikurippu R: 6 articles (06/2011 - 01/2007)|
|7.||Miyamoto, Masaomi: 6 articles (08/2009 - 11/2004)|
|8.||Zammit, Gary: 6 articles (04/2009 - 01/2006)|
|9.||Spence, D Warren: 5 articles (06/2011 - 01/2007)|
|10.||Hirai, Keisuke: 4 articles (01/2014 - 11/2004)|
|1.||Sleep Initiation and Maintenance Disorders (Insomnia)
06/15/2011 - "In this case series of 5 alcohol-dependent patients with insomnia who had initiated abstinence, a 4-week course of ramelteon 8 mg nightly was associated with markedly improved insomnia scores, increased total sleep time, and decreased time to fall asleep. "
01/01/2005 - "In three clinical trials in patients with chronic insomnia, ramelteon 8mg was effective in reducing sleep latency, without being associated with any significant or clinically relevant residual effects. "
02/01/2011 - "In Japanese adults with chronic insomnia, ramelteon 8 mg significantly reduced patient-reported sleep latency, increased total sleep time and improved sleep quality after 1 week of treatment. "
07/01/2008 - "In this post hoc analysis of data from patients with chronic insomnia, a significantly greater percentage experienced a > or = 50% reduction in LPS with ramelteon 8 mg/d versus placebo. "
01/01/2006 - "Ramelteon demonstrated a statistically significant reduction in LPS and a statistically significant increase in TST, with no apparent next-day residual effects, in patients with chronic primary insomnia."
12/01/2012 - "Marked improvement in delirium with ramelteon: five case reports."
03/01/2015 - "In this study, ramelteon was found to be beneficial in preventing delirium in medically ill individuals when compared to placebo. "
07/01/2011 - "These cases suggest that ramelteon may be beneficial in the treatment of delirium. "
01/01/2014 - "The aim of the present study was to determine the efficacy of ramelteon in elderly patients with delirium caused by different primary diseases/conditions. "
07/01/2011 - "The aim of the present study was to determine the efficacy of ramelteon for treating delirium. "
11/01/2007 - "However, the recent approval of Ramelteon for treatment of sleep disorders and the evaluation of other compounds in clinical trials have highlighted their clinical importance. "
06/01/2009 - "Ramelteon: a review of its therapeutic potential in sleep disorders."
02/01/2008 - "A review of ramelteon in the treatment of sleep disorders."
11/01/2004 - "Based on its unique mechanism of action, ramelteon should be studied further to evaluate its potential for the treatment of sleep disorders."
01/01/2013 - "Ramelteon had a systemic anti-inflammatory effect and improved sleep disorders and LUTS, suggesting that it may be a useful treatment for patients with LUTS-associated insomnia."
06/01/2013 - "From now on, we regard ramelteon as one of the new treatment choices for insomniac patients complicated with nocturia."
06/01/2013 - "[The onset mechanism of nocturia in the elderly and the possibility of ramelteon]."
01/01/2013 - "Ramelteon in combination with an α1-blocker could be a treatment option for reducing nocturia in men with BPH."
01/01/2013 - "The mean score on IPSS question 7 (nocturia) decreased significantly from 2.88 before starting ramelteon to 2.41 one month after starting the medication (P = 0.03). "
01/01/2013 - "We herein investigated the effects of ramelteon, an antioxidant and sleep inducer, on nocturia unresponsive to α1-blocker monotherapy in males with lower urinary tract symptoms (LUTS) as a pilot study. "
|5.||Chronic Obstructive Pulmonary Disease (COPD)
08/01/2008 - "In this study, ramelteon 16 mg (two times the recommended therapeutic dose) showed no clinically meaningful or statistically significant effects on oxygenation or abnormal breathing events, was well tolerated, and improved sleep duration and efficiency in subjects with mild to moderate COPD."
03/01/2009 - "Ramelteon did not produce respiratory depressant effects as measured by oxygenation or abnormal breathing events in subjects with moderate to severe COPD. "
03/01/2009 - "The effects of ramelteon on respiration during sleep in subjects with moderate to severe chronic obstructive pulmonary disease."
08/01/2008 - "This randomized, double-blind, crossover study in 26 subjects with mild to moderate COPD compared the effects of a single bedtime dose of ramelteon 16 mg and placebo on sleep, oxygenation, and sleep-related abnormal breathing events. "
08/01/2008 - "Effect of ramelteon, a selective MT(1)/MT (2)-receptor agonist, on respiration during sleep in mild to moderate COPD."
|2.||MT2 Melatonin Receptor
|3.||Melatonin Receptors (Melatonin Receptor)
|8.||S 20098 (agomelatine)
|9.||Hypnotics and Sedatives (Sedatives)
|2.||Drug Therapy (Chemotherapy)
|5.||Phytotherapy (Herbal Therapy)